Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy
BackgroundTight monitoring of efficacy and safety of anticoagulants such as warfarin is imperative to optimize the benefit-risk ratio of anticoagulants in patients. The standard tests used are measurements of prothrombin time (PT), usually expressed as international normalized ratio (INR), and activ...
Saved in:
Main Authors: | Sonja Hartmann (Author), Konstantinos Biliouris (Author), Lawrence J. Lesko (Author), Ulrike Nowak-Göttl (Author), Mirjam N. Trame (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia
by: Derseh MT, et al.
Published: (2021) -
The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016) -
Efficacy and safety of rivaroxaban versus warfarin in the management of unusual site deep vein thrombosis: a retrospective cohort study
by: Linlin Fu, et al.
Published: (2024) -
Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study
by: André R. Durães, et al.
Published: (2018) -
RIVAROXABAN USE IN THE TREATMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM
by: A. D. Erlikh
Published: (2020)